Advertisement

Im Focus Onkologie

, Volume 21, Issue 4, pp 54–62 | Cite as

Besondere klinische Herausforderung

ZNS-Befall bei Patienten mit NSCLC

  • Niels Reinmuth
  • Florian Würschmidt
Pneumoonkologie Zertifizierte Fortbildung

Zusammenfassung

Ungefähr die Hälfte aller Patienten mit nichtkleinzelligem Lungenkarzinom entwickelt im Krankheitsverlauf zereabrale Metastasen. Sie stellen eine besondere klinische Herausforderung dar. Weiterentwicklungen im Hinblick auf Resektionsverfahren, Bestrahlungsmodalitäten und neue Substanzen kommen aber auch diesen Patienten zugute.

Literatur

  1. 1.
    Inno A et al. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(6):599–609.CrossRefGoogle Scholar
  2. 2.
    Reinmuth N et al. [Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer]. Pneumologie. 2018;72(2):138–54.CrossRefGoogle Scholar
  3. 3.
    Wen PY et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80(3):313–32.CrossRefGoogle Scholar
  4. 4.
    Gaspar L et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.CrossRefGoogle Scholar
  5. 5.
    Mulvenna P et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14.CrossRefGoogle Scholar
  6. 6.
    Barker FG 2nd. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100(5):999–1007.CrossRefGoogle Scholar
  7. 7.
    Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12(7):884–98.CrossRefGoogle Scholar
  8. 8.
    Patchell RA et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.CrossRefGoogle Scholar
  9. 9.
    Brown PD et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC•3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–60.CrossRefGoogle Scholar
  10. 10.
    Mahajan A et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–8.CrossRefGoogle Scholar
  11. 11.
    Brown PD et al. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol. 2018;36(5):483–91.CrossRefGoogle Scholar
  12. 12.
    Stark AM et al. Surgical treatment for brain metastases: prognostic factors and survival in 177 patients. Neurosurg Rev. 2005;28(2):115–9.CrossRefGoogle Scholar
  13. 13.
    Paek SH et al. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005;56(5):1021–34; discussion 1021-34.PubMedGoogle Scholar
  14. 14.
    Khuntia D et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8):1295–304.CrossRefGoogle Scholar
  15. 15.
    Brown PD et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316(4):401–9.CrossRefGoogle Scholar
  16. 16.
    Soffietti R et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65–72.CrossRefGoogle Scholar
  17. 17.
    Chang EL et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.CrossRefGoogle Scholar
  18. 18.
    DeAngelis LM et al. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–96.CrossRefGoogle Scholar
  19. 19.
    Sahgal A et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91(4):710–7.CrossRefGoogle Scholar
  20. 20.
    Patchell RA et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.CrossRefGoogle Scholar
  21. 21.
    Prokic V et al. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013;85(1):264–70.CrossRefGoogle Scholar
  22. 22.
    Mittapalli RK et al. Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors. Cancer Res. 2017;77(2):238–46.CrossRefGoogle Scholar
  23. 23.
    Bernardo G et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from nonsmall-cell lung cancer: a phase II study. Cancer Invest. 2002;20(3):293–302.CrossRefGoogle Scholar
  24. 24.
    Minotti V et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer. 1998;20(2):93–8.CrossRefGoogle Scholar
  25. 25.
    Franciosi V et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85(7):1599–605.CrossRefGoogle Scholar
  26. 26.
    Fujita A et al. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology. 2000;59(4):291–5.CrossRefGoogle Scholar
  27. 27.
    Cortes J et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2003;64(1):28–35.CrossRefGoogle Scholar
  28. 28.
    Barlesi F et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22(11):2466–70.CrossRefGoogle Scholar
  29. 29.
    Dinglin XX et al. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol. 2013;112(3):461–6.CrossRefGoogle Scholar
  30. 30.
    Moro-Sibilot D et al. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer. 2015;90(3):427–32.CrossRefGoogle Scholar
  31. 31.
    Robinet G et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12(1):59–67.CrossRefGoogle Scholar
  32. 32.
    Dempke WC et al. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Anticancer Res. 2015;35(11):5797–806.PubMedGoogle Scholar
  33. 33.
    Broniscer A et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res. 2007;13(5):1511–5.CrossRefGoogle Scholar
  34. 34.
    Proto C et al. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from nonsmall cell lung cancer: the present and the future. Transl Lung Cancer Res. 2016;5(6):563–78.CrossRefGoogle Scholar
  35. 35.
    Milton DT et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer. 2006;107(5):1034–41.CrossRefGoogle Scholar
  36. 36.
    Wu C et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007;57(3):359–64.CrossRefGoogle Scholar
  37. 37.
    Grommes C et al. „Pulsatile“ high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13(12):1364–9.CrossRefGoogle Scholar
  38. 38.
    Welsh JW et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-smallcell lung cancer. J Clin Oncol. 2013;31(7):895–902.CrossRefGoogle Scholar
  39. 39.
    Hoffknecht P et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156–63.CrossRefGoogle Scholar
  40. 40.
    Schuler M et al. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016;11(3):380–90.CrossRefGoogle Scholar
  41. 41.
    Soria JC et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–25.CrossRefGoogle Scholar
  42. 42.
    Solomon BJ et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol. 2016;34(24):2858–65.CrossRefGoogle Scholar
  43. 43.
    Costa DB et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015;33(17):1881–8.CrossRefGoogle Scholar
  44. 44.
    De Castro et al. First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). J Thorac Oncol. 2016;12(1, Suppl):Abstr PL03.07.Google Scholar
  45. 45.
    Gadgeel SM et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(34):4079–85.CrossRefGoogle Scholar
  46. 46.
    Peters S et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:829–838.CrossRefGoogle Scholar
  47. 47.
    Magnuson WJ et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol. 2017;35(10):1070–7.CrossRefGoogle Scholar
  48. 48.
    Soon YY et al. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2015;114(2):167–72.CrossRefGoogle Scholar
  49. 49.
    Tsakonas G et al. Management of brain metastasized non-small cell lung cancer (NSCLC) — From local treatment to new systemic therapies. Cancer Treat Rev. 2017;54:122–31.CrossRefGoogle Scholar
  50. 50.
    Berghoff AS et al. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. Am Soc Clin Oncol Educ Book. 2016;35:e116–22.CrossRefGoogle Scholar
  51. 51.
    Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.CrossRefGoogle Scholar
  52. 52.
    Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Asklepios Fachkliniken München-GautingGautingDeutschland
  2. 2.Radiologische Allianz HamburgHamburgDeutschland

Personalised recommendations